EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang iD

Neuroprotection · 08.06.2026

DOI: 10.1002/nep3.70041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuroprotection, online erschienen am 08.06.2026. Verfasst von Tianshan Ji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Basic Medical Science Nanjing Medical University Nanjing Jiangsu China. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Basic Research Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template. It enables precise base substitutions, small insertions, and deletions without introducing double‐strand breaks, thereby expanding the range of correctable mutations while reducing undesired repair outcomes. This technology offers a promising strategy for genomic correction in the nervous system. Here, we review the development of prime editing, its mechanistic rationale, and emerging preclinical evidence that supports its application in neuropsychiatric disorders. We discuss key biological and technological barriers, including limited editing efficiency in post‐mitotic neurons, complex pegRNA design, reverse transcription‐related errors, vector payload limitations, and blood‐brain barrier (BBB) penetration. Nevertheless, in vitro and in vivo studies have demonstrated proof‐of‐concept correction and functional rescue in several monogenic neurodevelopmental disorders. Advances such as split‐adeno‐associated virus (AAV) systems, lipid nanoparticles, engineered peptides, and compact Cas variants are actively expanding their therapeutic potential. Further clinical translation will rely on improved editors with guide engineering, BBB‐penetrant and neuron‐targeted delivery platforms, transient or cell‐type‐specific expression strategies, and comprehensive genome‐wide safety evaluations.

Schlagwörter

Stichwörter der Autor:innen

genetic therapymental disordersneurodevelopmental disordersprime editing

Autor:innen und Institutionen

  • Department of Physiology, School of Basic Medical Science Nanjing Medical University Nanjing Jiangsu China.
  • Jiangsu Provincial Key Laboratory of Biological Therapy for Organ Failure, School of Basic Medical Science Nanjing Medical University Nanjing Jiangsu China.
  • Tianyuan Honors School Nanjing Medical University Nanjing Jiangsu China.
  • The First School of Clinical Medicine Nanjing Medical University Nanjing Jiangsu China.
  • The Second School of Clinical Medicine Nanjing Medical University Nanjing Jiangsu China.

ORCID-Profile: Chengkun Wang

Förderung

  • National Basic Research Program of China

Zitieren

APA

Ji, T., Zhang, Y., Zhao, J., Lu, Y., & Wang, C. (2026). Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation. Neuroprotection. https://doi.org/10.1002/nep3.70041

Vancouver

Ji T, Zhang Y, Zhao J, Lu Y, Wang C. Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation. Neuroprotection. 2026. doi:10.1002/nep3.70041

BibTeX
@article{Ji2026,
  author = {Ji, Tianshan and Zhang, Yuan and Zhao, Jinyi and Lu, Yiping and Wang, Chengkun},
  title = {Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation},
  journal = {Neuroprotection},
  year = {2026},
  doi = {10.1002/nep3.70041}
}
Kostenlos starten →